# Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy

## TL;DR

This paper explores NADPH oxidases as potential new treatments for early-stage diabetic retinopathy by targeting oxidative stress in the neurovascular unit.

## Contribution

The paper introduces NADPH oxidases (NOX1-NOX5) as novel therapeutic targets for early-stage diabetic retinopathy.

## Key findings

- NADPH oxidases contribute to oxidative stress in the impaired neurovascular unit during early diabetic retinopathy.
- Specific inhibitors of NOX2 and NOX4 show potential for neuroprotection against diabetic insults.
- Targeting NOX enzymes may prevent or delay progression to advanced diabetic retinopathy.

## Abstract

Diabetic Retinopathy is the most common microvascular complication of diabetes. The Neurovascular Unit (NVU) is brought to the surface for its importance to retinal physiological function. Diabetes impairs the NVU through diverse causative factors, such as ischemia, oxidative stress, and excitotoxicity. The interplay between members of the above triad leads to the main pathological factors of Diabetic Retinopathy—namely, neurodegeneration, neuroinflammation, and vasculopathy. Emphasis is given to the pathology of the early stage of Diabetic Retinopathy (ESDR) and the putative new therapeutic treatments that will prevent/delay the development of the advanced stage of the disease, in which vision is compromised. NADPH oxidases (NOX1-NOX5), whose main function is to produce reactive oxygen species and induce oxidative/nitrative stress will be presented as novel therapeutic targets for the impaired Neurovascular Unit. The knowledge of the molecular mechanisms involved in the neuroprotection induced by novel specific inhibitors of NOX2 and NOX4 against the diabetic insults will confer the hope that therapeutic treatments for ESDR will evolve in the near future and be beneficial to millions of subjects who are in the early stage of Diabetic Retinopathy, as well as subjects with other complications of diabetes.